immunotherapy Articles
-
The power of autoantibodies as biomarkers of the immune response to cancer
How autoantibody profiling can further unlock the success of CPI therapy Immunotherapy has revolutionised the treatment of cancers, improving the prognosis for a variety of malignancies. One of the key elements in the immunotherapy war chest are checkpoint inhibitors (CPIs) which have been the main drivers behind this progress. These pioneering drugs, however, are not perfect, with a ...
-
Advancing Cancer Treatments with ALZET Osmotic Pumps
The research summarized in this whitepaper provides a number of examples of how ALZET® pumps offer a superior pre-clinical drug dosing option for the delivery of a wide array of anti-cancer agents, including small molecules, immunotherapies, radiotherapies, combination treatments, and novel drug entities. This whitepaper also explores how ALZET® pumps have been used to successfully test ...
-
New Breakthrough in Cancer Cell Research
The body's immune system is an effective weapon against disease, and immunotherapy of cancer cell research is the current frontier in the treatment of cancer and other diseases. Recently, researchers at Notre Dame University have identified specific features of the reaction of two distinct peptide antigens to a T-cell receptor (TCR), which provides new clues to optimizing molecular structure ...
-
Navigating Cancer’s, Dr. Amila Patel, Provides Insight on Racial Disparities in Recent Cancer Treatment Study
Navigating Cancer, Chief Clinical & Strategy Officer, Dr. Amila Patel, PharmD, BCOP, recently presented data on key findings from a recent abstract with Duke Health revealing racial disparities among head and neck cancer populations at the 2022 American Society of Clinical Oncology conference. Our research, along with our partners at Duke Health, found there were significant health care ...
-
Beyond Just Peptide Antigens: The complex world of peptide-based cancer vaccines
Therapeutic vaccines may well be the next wave of immunotherapy for cancer treatment. Peptide-based vaccines will play a pivotal role in the field. How is a peptide vaccine designed? What other factors such as adjuvants etc should be considered? Can Immunol oncological agents be synergetic with peptide vaccines? Read the full article: Beyond Just Peptide Antigens: The complex world of ...
-
Natural Killer Cells May Be Scaled and Engineered as a Next Generation, Off-the-Shelf Cell Therapy for Cancer
The advent of immunotherapies for cancer, and more recently of cellular immunotherapies, has substantially altered the treatment landscape. In hematological malignancies, complete response rates to CAR-T cells can exceed 80%. These responses are often durable in nature and have attracted considerable excitement and investment in the development of cell therapies for an expanded range of ...
By Nkarta, Inc.
-
Ildong’s subsidiary secures 1st anticancer drug pipeline
Idience, a subsidiary of Ildong Pharmaceutical, has acquired IDX-1197, an immunotherapy drug, as its first pipeline. The introduction of the new pipeline came four months after Ildong Pharmaceutical established Idience as a no research and development only (NRDO) company in May. With the acquisition, Idience has decided to launch phase 1b and 2a clinical trial for the drug this year, which will ...
-
Going beneath the surface of skin cancer - Case study
Summary In this Cell Patterns publication, Ozette co-founders and collaborators at the Cancer Immunotherapy Trials Network (CITN) outline a novel method of analysis of single cell data, FAUST, and validate the multiple potential applications. The paper tackles 2 important problems: 1) analysis of complex single cell datasets; 2) prediction of response to immunotherapy in cancer. Manual ...
-
Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
A population of NK cells expressing the activating receptor NKG2C and the maturation marker CD57 expands in response to human CMV (HCMV) infection. CD3–CD56dimCD57+NKG2C+ NK cells are similar to CD8+ memory T cells with rapid and robust effector function upon restimulation, persistence, and epigenetic remodeling of the IFNG locus. Chronic antigen stimulation drives CD8+ memory T cell ...
-
Technical Talk: Explore Next-Generation Nuclear Localization Signal Therapeutics
Creative Biolabs, as a top-ranked solution provider of antibody-drug conjugate, scheduled a webinar about improved nuclear localization signal-therapeutics, which went live on January 21, 2022. Antibody-drug conjugate (ADC) has gained booming attention in the past 2021, with multiple international strategic purchases and breakthrough results of both preclinical and clinical trials. As a ...
-
Regulation of cancer by therapeutic vaccination and dietary bio-modulation involving organ-specific mitochondria
Cancer therapy should aim to prevent recurrent disease. Surgery and toxic treatments remove only symptoms associated with cancer without trying to intervene in the aetiology, therefore the disease may recur. The autologous cancer vaccine supplemented with bio-modulation might fulfil requirements for effective tumour therapy. The autologous tumour vaccine is formed in the same way as our bodily ...
-
Oral mucosal immunotherapy for allergic rhinitis: A pilot study
Abstract Background: The sublingual mucosa has been used for many years to apply allergenic extracts for the purpose of specific immunotherapy (IT). Although sublingual IT (SLIT) is both safe and efficacious, the density of antigen-presenting cells is higher in other regions of the oral cavity and vestibule, which make them a potentially desirable target for IT. Objective: To present the concept ...
-
Treos Bio Announces the Publication of Preclinical Data in Frontiers in Genetics Showing its COVID-19 Peptide Vaccine Mimics the Diversity of T Cell Immunity Produced by Natural SARS-CoV-2 Infection
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate Tailored to Individuals’ Genetics ...
-
Targeting Interleukin-6 Helps to Mitigate the Side Effects of Immunotherapy
Researchers at The University of Texas MD Anderson Cancer Center have identified a new strategy to reduce immune-related adverse events by targeting immunotherapy with the cytokine interleukin-6 (IL-6). The study, published in Cancer Cell, provides evidence for the concept of combining immune checkpoint blockers and cytokine blockers to selectively inhibit inflammatory autoimmune responses. ...
-
Immune Strategies for Cancer Treatment
In the search for innovative and effective ways to target cancer, we are faced with more than just a challenging problem; we are faced with our own cells as opponents. Cancer cells evolve to achieve an optimum of physical fitness, giving them an array of abilities that no cell should possess in a healthy organism. One way to find novel therapies against cancer therefore could imply finding a ...
-
OCD: an "autoimmune disease"
Obsessive-compulsive disorder (OCD) is a serious and common psychiatric disorder with a prevalence of approximately 1-3% in adults. The onset of OCD has a bimodal age distribution, usually manifesting first in late childhood and early adolescence and later appearing in early adulthood. OCD is a multifactorial disorder with an interplay of biological, psychological, and external factors, and ...
-
CD Genomics Supports Immune and Cancer Research with TCR-Seq Service
CD Genomics is a world-leading genomics services company that continues to innovate in high throughput sequencing services for the genomics industry, as well as genotyping, bioinformatics, microarrays, and more. The company has recently launched TCR-seq, a powerful service that enables rapid and efficient analysis of T-cell receptor (TCR) diversity and clonality, providing critical support for ...
By CD Genomics
-
Comparative effect of an immunomodulator Immunoxel (DzhereloT) when used alone or in combination with antiretroviral therapy in drug-naive HIV-infected individuals
Immunomodulating agent Immunoxel (Dzherelo) has been evaluated in 70 HIV-positive individuals divided into three arms: first, control arm, received standard antiretroviral therapy zidovudine/lamivudine/efavirenz (AZT7/3TC/EFV); second-AZT/3TC/EFV+Immunoxel and third, Immunoxel alone, given orally, twice daily. At 32 weeks of follow-up CD4 cell counts increased in all arms, reaching + 102, +190 ...
-
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Abstract Viral infection of the liver is a major risk factor for hepatocellular carcinoma (HCC). Natural killer (NK) cells recognize virally infected and oncogenically transformed cells, suggesting a therapeutic role for NK-cell infusions in HCC. Using the K562-mb15-41BBL cell line as a stimulus, we obtained large numbers of activated NK cells from the peripheral blood of healthy donors. ...
By Nkarta, Inc.
-
B7-H3: Broad Prospects of Emerging Tumor Immunotherapy Targets
Recently, in the renowned academic journal Nature Medicine, the Kimmel Cancer Center at Johns Hopkins University published Phase 2 clinical results regarding enoblituzumab, a monoclonal antibody targeting B7-H3, for the treatment of prostate cancer. The results demonstrate that enoblituzumab can successfully induce the body's anti-cancer activity, showing favorable therapeutic efficacy and safety ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you